Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registry.

Fecha de publicación: Fecha Ahead of Print:

Autores de IDIVAL

  • Almudena García Castaño

    Autor

Autores ajenos al IDIVAL

  • Gonzalez-Cao M
  • Berciano-Guerrero MÁ
  • Muñoz-Couselo E
  • Manzano JL
  • Cerezuela-Fuentes P
  • Crespo G
  • Soria A
  • de Miguel PA
  • Gutiérrez Sanz L
  • de la Rosa CA
  • Puértolas T
  • Espinosa E
  • Medina J
  • Bellido L
  • Berrocal A
  • Majem M
  • López Castro R
  • Fernandez LA
  • Garcia F
  • de la Borbolla MR
  • Martín Algarra S
  • Márquez-Rodas I

Unidades

Abstract

BACKGROUND: Acral melanoma (AM) is uncommon in non-Asian race. Limited data exist in non-Asian population. OBJECTIVE: To analyze the activity of immunotherapy in patients diagnosed with AM in Spain. METHODS: We analyzed clinical outcomes of AM in the nationwide Spanish Melanoma Group Registry. RESULTS: 69 AM (17 stage III; 52 stage IV) and 724 cutaneous melanoma (CM) (190 stage III; 534 stage IV), predominantly non-Hispanic white. Regarding stage IV, AM patients were older (median 73.6 vs. 66.6 years, p = 0.001) and less often BRAF mutant (9.6% vs. 60.7%, p = 0.0001). First line immunotherapy (49 AM; 316 CM), response rate was 15.0% vs 39.1% (p = 0.0033), median progression free survival was 5.5 (95% CI 3.97-8.23) vs 15.3 months (95% CI 8.97- 26.3) (p = 0.001) and median OS was 17.3 (95% CI 13.32-39.97) versus 43.0 months (95% CI 30.81, NR) (p = 0.007), for AM and CM, respectively. Stage III AM were deeper (T4b in 52.9% vs. 25.3%, p = 0.02). In adjuvant anti PD-1-treated patients (14 AM; 156 CM) median RFS was 10.23 months (95% CI 6.0-NR) in AM versus NR (54.5-NR) in CM (p = 0.017) and 5 year OS was 36.1% vs. 75.8% (p = 0.034). CONCLUSIONS: Our data confirms a poor outcome of AM in the Spanish population.

© 2025. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).

Datos de la publicación

ISSN/ISSNe:
1699-048X, 1699-3055

CLINICAL & TRANSLATIONAL ONCOLOGY  SPRINGER INT PUBL AG

Tipo:
Article
Páginas:
645-653
PubMed:
40841506

Citas Recibidas en Web of Science: 1

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Acral melanoma; Anti PD-1 Ab; Real world data

Cita

Compartir